To review the current clinical-stage therapies in development for geographic atrophy (GA) associated with age-related macular degeneration (AMD).
Key Findings:
Pegcetacoplan and Avacincaptad pegol have shown modest reductions in lesion growth in clinical trials, with specific percentages noted.
Vonaprument is currently being tested for its ability to prevent vision loss, with expected outcomes from the ongoing trials.
Elamipretide has shown some functional improvements despite not meeting primary endpoints in trials, indicating potential for further research.
Gene therapies like JNJ-81201887 and CTx001 are in various stages of clinical evaluation, with specific trial phases and goals outlined.
Interpretation:
The development of therapies for GA reflects a shift towards targeting specific disease mechanisms, particularly through complement inhibition and gene therapy, with the potential for more effective and durable treatments.
Limitations:
Long-term safety and efficacy data for new therapies are still pending, which may affect clinical adoption.
Some therapies have shown only modest efficacy in reducing lesion growth, raising questions about their overall impact on patient outcomes.
Conclusion:
The therapeutic landscape for GA is evolving with promising investigational therapies that may offer improved outcomes for patients suffering from this debilitating condition.
